Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing
great interest in the neuro-oncology community. While several reports show that subsets of …
great interest in the neuro-oncology community. While several reports show that subsets of …
CD8+ T cell states in human cancer: insights from single-cell analysis
AM Van der Leun, DS Thommen… - Nature Reviews …, 2020 - nature.com
The T cell infiltrates that are formed in human cancers are a modifier of natural disease
progression and also determine the probability of clinical response to cancer …
progression and also determine the probability of clinical response to cancer …
[HTML][HTML] Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages
Clear cell renal carcinoma (ccRCC) is a heterogeneous disease with a variable post-
surgical course. To assemble a comprehensive ccRCC tumor microenvironment (TME) …
surgical course. To assemble a comprehensive ccRCC tumor microenvironment (TME) …
The immunology of renal cell carcinoma
CM Díaz-Montero, BI Rini, JH Finke - Nature Reviews Nephrology, 2020 - nature.com
Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …
Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma
The management of advanced-stage renal cell carcinoma (RCC) has been transformed by
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
ZR Huinen, EJM Huijbers, JR van Beijnum… - Nature Reviews …, 2021 - nature.com
Immune checkpoint inhibitors have revolutionized medical oncology, although currently only
a subset of patients has a response to such treatment. A compelling body of evidence …
a subset of patients has a response to such treatment. A compelling body of evidence …
Tertiary lymphoid structures in the era of cancer immunotherapy
C Sautès-Fridman, F Petitprez, J Calderaro… - Nature Reviews …, 2019 - nature.com
Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-
lymphoid tissues at sites of chronic inflammation including tumours. Key common …
lymphoid tissues at sites of chronic inflammation including tumours. Key common …
A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma
J Wu, L Li, H Zhang, Y Zhao, H Zhang, S Wu, B Xu - Oncogene, 2021 - nature.com
Tumor microenvironment (TME) has been reported to exhibit a crucial effect in lung cancer.
Therefore, this study was aimed to investigate the genes associated with TME and develop a …
Therefore, this study was aimed to investigate the genes associated with TME and develop a …
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics
Clear cell renal cell carcinoma (ccRCC) is one of the most immunologically distinct tumor
types due to high response rate to immunotherapies, despite low tumor mutational burden …
types due to high response rate to immunotherapies, despite low tumor mutational burden …
Biomaterials tools to modulate the tumour microenvironment in immunotherapy
Y Chao, Z Liu - Nature Reviews Bioengineering, 2023 - nature.com
Cancer immunotherapies, such as immune checkpoint blockade and chimeric antigen
receptor (CAR) T cell therapy, have transformed clinical oncology. However, limited patient …
receptor (CAR) T cell therapy, have transformed clinical oncology. However, limited patient …